<unk>  was approved for glycemic control in people with type 2 diabetes, as measured by glycated haemoglobin A1c (HbA1c) as a surrogate endpoint, similar to that of other oral antidiabetic drugs. The controversy over adverse effects has dramatically reduced the use of<unk> . Published studies did not provide evidence that outcomes like mortality, morbidity, adverse effects, costs and health-related quality of life are positively influenced by<unk> .
Rosiglitazone
Pioglitazone
Metformin
Liraglutide
Glibenclamide
Exenatide
Acarbose
Miglitol